Clinical Trial

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-09.
Status change: Not Yet Recruiting → Recruiting 2026-03-25
Trial Details
NCT Number NCT06868732
Lead Sponsor Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Conditions Advanced Non-small Cell Lung Cancer
Enrollment 288 participants
Start Date 2025-04-02
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-30